Literature DB >> 11709794

The white morphotype of Mycobacterium avium-intracellulare is common in infected humans and virulent in infection models.

S Mukherjee1, M Petrofsky, K Yaraei, L E Bermudez, G A Cangelosi.   

Abstract

Isolates of Mycobacterium avium-intracellulare (MAI) form multiple colony types named red-opaque, white-opaque, red-transparent (RT), and white-transparent (WT). The newly discovered WT morphotype is multidrug resistant relative to other variants in vitro. To determine whether the WT morphotype occurs in humans, 32 MAI-positive clinical samples from 2 sites were plated directly onto indicator agar without prior passage in vitro. WT was the predominant morphotype in 26 (81%) of these samples and was absent in only 2 samples. WT variants grew better than isogenic RT variants in mouse and human macrophage models of infection, and RT clones that passed through such systems underwent rapid shifts to the WT morphotype. The RT morphotype was heterogeneous with regard to infectivity. In summary, the white morphotype was common in humans and was favored in disease models. It may play an important role in the establishment and persistence of MAI infection.

Entities:  

Mesh:

Year:  2001        PMID: 11709794     DOI: 10.1086/324523

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  The two-component regulatory system mtrAB is required for morphotypic multidrug resistance in Mycobacterium avium.

Authors:  Gerard A Cangelosi; Julie S Do; Robert Freeman; John G Bennett; Makeda Semret; Marcel A Behr
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Inactivation of Mycobacterium avium complex by UV irradiation.

Authors:  Gwy-Am Shin; Jung-Keun Lee; Robert Freeman; Gerard A Cangelosi
Journal:  Appl Environ Microbiol       Date:  2008-09-26       Impact factor: 4.792

3.  Roles for cell wall glycopeptidolipid in surface adherence and planktonic dispersal of Mycobacterium avium.

Authors:  Robert Freeman; Henriette Geier; Kris M Weigel; Julie Do; Timothy E Ford; Gerard A Cangelosi
Journal:  Appl Environ Microbiol       Date:  2006-09-29       Impact factor: 4.792

4.  Shared Mycobacterium avium genotypes observed among unlinked clinical and environmental isolates.

Authors:  M Ashworth Dirac; Kris M Weigel; Mitchell A Yakrus; Annie L Becker; Hui-Ling Chen; Gina Fridley; Arthur Sikora; Cate Speake; Elizabeth D Hilborn; Stacy Pfaller; Gerard A Cangelosi
Journal:  Appl Environ Microbiol       Date:  2013-07-12       Impact factor: 4.792

5.  Genes required for intrinsic multidrug resistance in Mycobacterium avium.

Authors:  Julie S Philalay; Christine O Palermo; Kirsten A Hauge; Tige R Rustad; Gerard A Cangelosi
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

6.  Mutational analysis of cell wall biosynthesis in Mycobacterium avium.

Authors:  Jean-Pierre Laurent; Kirsten Hauge; Kellie Burnside; Gerard Cangelosi
Journal:  J Bacteriol       Date:  2003-08       Impact factor: 3.490

7.  Isolation of the genome sequence strain Mycobacterium avium 104 from multiple patients over a 17-year period.

Authors:  Kathleen L Horan; Robert Freeman; Kris Weigel; Makeda Semret; Stacy Pfaller; Terry C Covert; Dick van Soolingen; Sylvia C Leão; Marcel A Behr; Gerard A Cangelosi
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

8.  Evaluation of a high-throughput repetitive-sequence-based PCR system for DNA fingerprinting of Mycobacterium tuberculosis and Mycobacterium avium complex strains.

Authors:  Gerard A Cangelosi; Robert J Freeman; Kaeryn N Lewis; Devon Livingston-Rosanoff; Ketan S Shah; Sparrow Joy Milan; Stefan V Goldberg
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

9.  Illegitimate recombination: an efficient method for random mutagenesis in Mycobacterium avium subsp. hominissuis.

Authors:  Faisal Asghar Khattak; Ashutosh Kumar; Elisabeth Kamal; Ralph Kunisch; Astrid Lewin
Journal:  BMC Microbiol       Date:  2012-09-11       Impact factor: 3.605

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.